FDA Examining Citizen Petition Review Process To Speed Generic Approvals
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency is looking at its review process for citizen petitions to expedite decisionmaking, but FDA has not settled on a course of action, Acting Commissioner Crawford and CDER Acting Director Galson tell GPhA. Citizen petitions have “got me losing sleep at night,” OGD Director Buehler says.
You may also be interested in...
Duragesic, Generics May Warrant Risk Management Plans, FDA Says
The agency will continue to monitor incidents of abuse or misuse of fentanyl transdermal systems and "may consider" requesting brand and generic manufacturers to implement a voluntary risk management plan, FDA says in denying citizen petition requests to delay approval of Duragesic generics.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
McKindler? New Pfizer CEO Echoes McKinnell’s Views On Payers, Scale
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said